Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US-2018161271-A1 · Jun 14, 2018 · US
Controlled release injectable ondansetron formulations
US12508247B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12508247-B2 |
| Application number | US-202017763205-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 30, 2020 |
| Priority date | Oct 1, 2019 |
| Publication date | Dec 30, 2025 |
| Grant date | Dec 30, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a controlled release injectable ondansetron formulation comprising ondansetron or pharmaceutically acceptable salt, derivative or metabolite thereof which releases ondansetron over a period of at least 2 days period from the date of administration and the process for preparation thereof.
First claim
Opening claim text (preview).
We claim: 1 . A controlled release injectable ondansetron formulation consisting of (a) 20 mg/mL to 180 mg/mL ondansetron, (b) 1 mg/mL to 15 mg/mL carboxymethyl cellulose or its sodium salt, (c) 1 mg/mL to 15 mg/mL phosphatidyl choline, (d) ethanol and (e) water.
Assignees
Inventors
Classifications
Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623) · CPC title
comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543}) · CPC title
- A61K9/0019Primary
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids · CPC title
Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12508247B2 cover?
- The present invention relates to a controlled release injectable ondansetron formulation comprising ondansetron or pharmaceutically acceptable salt, derivative or metabolite thereof which releases ondansetron over a period of at least 2 days period from the date of administration and the process for preparation thereof.
- Who is the assignee on this patent?
- Shilpa Medicare Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K9/0019. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).